Obinutuzumab (Synonyms: 奥滨尤妥珠单抗; GA101; Anti-Human CD20 type II, Humanized Antibody)

目录号: HY-P9910 纯度: ≥99.4%: Data Sheet SDS COA
FAQs
技术支持

Obinutuzumab (GA101) 是一种 II 型 CD20 人源化 IgG1 单克隆抗体，用于非霍奇金淋巴瘤的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥2450	In-stock
5 mg	￥7000	In-stock
10 mg	￥10500	In-stock
25 mg	￥17200	In-stock
50 mg		询价
100 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Obinutuzumab Featured Recommendations:

Obinutuzumab 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Obinutuzumab (GA101) a Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

IC₅₀ & Target

CD20/MS4A1

体外研究
(In Vitro)

在诱导直接细胞死亡方面，Obinutuzumab 优于 Rituximab 和 Ofatumumab（该作用独立于抗体处理后所需的细胞团块破碎操作），但在介导补体依赖性细胞毒作用 (CDC) 方面，其效力比 Rituximab 和 Ofatumumab 低 10 至 1000 倍。Obinutuzumab 在抗体依赖性细胞介导的细胞毒作用 (ADCC) 和全血 B 细胞清除实验中均优于 Rituximab 和 Ofatumumab，在抗体依赖性细胞吞噬作用 (ADCP) 中则与二者相当。此外，Obinutuzumab 与 CD20 结合后其内吞速率慢于 Rituximab 和 Ofatumumab^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在相同剂量下，Obinutuzumab 对已建立的 RL 肿瘤的抗肿瘤活性优于 Rituximab。Obinutuzumab 对 RL 异种移植瘤的抗肿瘤作用表现出剂量依赖性，其肿瘤生长抑制率 (TGI) 按 NCI 公式在第 34 天计算，分别为 10、30 和 100 mg/kg 剂量下的 25%、75% 和 85%。在剂量为 30 和 100 mg/kg 时，Obinutuzumab 可显著抑制 RL 肿瘤生长，并分别在 10% 和 30% 的小鼠中诱导完全缓解。此类给药方案的耐受性良好，未观察到体重的显著变化^[2]。 Obinutuzumab 在 SU-DHL4 模型中可诱导强效抗肿瘤反应，包括完全缓解，其整体疗效优于 Rituximab 和 Ofatumumab^[1]。 Obinutuzumab 联合 Bendamustine 相较于 Rituximab 联合 Bendamustine 可实现更强的肿瘤生长抑制效果，并且与各自单药治疗相比具有统计学显著性。Obinutuzumab 联合化疗的疗效优于各自的单药治疗^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

基因 ID

931 [NCBI]

Accession

P11836

应用

ELISA, FACS, Functional assay

偶联物

Unconjugated

复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.

分子量

146.32 kDa

CAS 号

949142-50-1

性状

液体

颜色

Colorless to light yellow

中文名称

奥滨尤妥珠单抗；阿托珠单抗；奥拓珠单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa

Biological Activity

Obinutuzumab has a significant ADCC effect on Raji cells in a dose-dependent manner.The EC₅₀ for this effect is 0.46 ng/mL.

纯度 & 产品资料

纯度: ≥99.4%

选择批次：

Data Sheet (542 KB) SDS (251 KB)

COA (265 KB)

抗体抑制剂使用指南 (1152 KB)

参考文献

[1]. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [Content Brief]

[2]. Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. [Content Brief]

[3]. Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. [Content Brief]

Animal Administration ^[2]	Mice: For xenograft experiments, 1×10⁶ RL cells are injected subcutaneously on day 1. Mice are randomized when a tumor becomes palpable in groups of 10 and treatment is initiated. In a first set of experiments, rituximab and obinutuzumab are used as monotherapy at different dosages twice weekly. The 5 different groups of 10 mice are: control group receiving vehicle (NaCl 0.9%), rituximab (30 mg/kg), obinutuzumab (10 mg/kg), obinutuzumab (30 mg/kg), and obinutuzumab (100 mg/kg). The treatment is administered intravenously twice a week. The mice are closely monitored regarding weight and general status^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [Content Brief] [2]. Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. [Content Brief] [3]. Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. [Content Brief]

Animal Administration
^[2]

Mice: For xenograft experiments, 1×10⁶ RL cells are injected subcutaneously on day 1. Mice are randomized when a tumor becomes palpable in groups of 10 and treatment is initiated. In a first set of experiments, rituximab and obinutuzumab are used as monotherapy at different dosages twice weekly. The 5 different groups of 10 mice are: control group receiving vehicle (NaCl 0.9%), rituximab (30 mg/kg), obinutuzumab (10 mg/kg), obinutuzumab (30 mg/kg), and obinutuzumab (100 mg/kg). The treatment is administered intravenously twice a week. The mice are closely monitored regarding weight and general status^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [Content Brief]

[2]. Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. [Content Brief]

[3]. Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. [Content Brief]

Obinutuzumab 相关分类

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Obinutuzumab949142-50-1GA101 Anti-Human CD20 type II, Humanized Antibody奥滨尤妥珠单抗阿托珠单抗奥拓珠单抗GA 101GA-101CD20Inhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Obinutuzumab (Synonyms: 奥滨尤妥珠单抗; GA101; Anti-Human CD20 type II, Humanized Antibody)

Customer Review

Obinutuzumab Featured Recommendations: